期刊
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
卷 7, 期 3, 页码 241-247出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11899-012-0130-5
关键词
Hematologic malignancy; Lymphomas; Hodgkin lymphoma; Hodgkin's disease; Classic Hodgkin lymphoma of the nodular sclerosis type; CHL-NS; Mediastinal lymphoma; Primary mediastinal large B-cell lymphoma; PMBL; Mediastinal gray zone lymphoma; MGZL; Gray zone lymphoma; GZL; Thymic B cell; Diffuse large B-cell lymphoma; DLBCL; Epigenetics; Gene expression profiling; Radiation therapy; Chemotherapy; Immunophenotyping; Microenvironment
资金
- National Cancer Institute
Although primary mediastinal large B-cell lymphoma (PMBL) and classic Hodgkin lymphoma of the nodular sclerosis type (CHL-NS) are distinct diseases, they share several clinical characteristics and biologic features. Given that, it is not surprising that there exist mediastinal lymphomas that do not fit well into either category but have clinical and morphologic features overlapping and transitional between PMBL and CHL-NS. The term mediastinal gray zone lymphoma (MGZL) has been used for these tumors, which are included in the World Health Organization classification as B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma. Although several studies have evaluated different therapeutic strategies in PMBL and CHL-NS, there is a paucity of prospective experience treating MGZL, given its rarity and relatively recent recognition. Historically, diseases that today would be categorized as MGZL were probably called anaplastic large-cell lymphoma Hodgkin-like, and their outcome with standard approaches was poor, with short overall survivals. In this review-following a discussion of the biology and clinical features of MGZL, and how they compare to PMBL and CHL-NS-we outline how the treatment of PMBL and CHL-NS has evolved in recent years, and how we believe MGZL should be approached therapeutically.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据